Mylan Urges Fed. Circ. To Keep Hatch-Waxman Venue Limits
Mylan Pharmaceuticals urged the full Federal Circuit on Tuesday not to review Valeant Pharmaceuticals' en banc petition challenging a panel's November ruling, which found that patent litigation over generic drugs is...To view the full article, register now.
Already a subscriber? Click here to view full article